Interaction between miR-142-3p and BDNF Val/Met Polymorphism Regulates Multiple Sclerosis Severity.

Area of Science:

• Neuroimmunology
• Genetics
• MicroRNA Therapeutics

Background:

• Multiple sclerosis (MS) is a complex CNS autoimmune disease with variable patient outcomes.
• MicroRNA-142-3p (miR-142-3p) is implicated in MS pathogenesis through its interaction with interleukin-1beta (IL1β), affecting excitotoxicity.
• Individual genetic variability may influence the impact of miR-142-3p on MS.

Purpose of the Study:

• To investigate the influence of the BDNF Val66Met polymorphism (rs6265) on the excitotoxic effects of miR-142-3p in MS.
• To explore the relationship between miR-142-3p, IL1β, and clinical parameters in MS patients with different BDNF genotypes.

Main Methods:

• Analysis of miR-142-3p and IL1β levels in cerebrospinal fluid (CSF) from 114 MS patients at diagnosis.
• Stratification of patients based on BDNF Val66Met (rs6265) genotype.
• Correlation analysis between molecular markers, genetic background, and MS clinical parameters (EDSS, MSSS, ARMSS, PI).

Main Results:

• In Met-carrier MS patients, miR-142-3p levels were decoupled from IL1β levels.
• This decoupling was also observed in relation to MS disease severity and progression metrics.
• The BDNF Val66Met polymorphism interferes with the IL1β-miR-142-3p axis in MS.

Conclusions:

• The BDNF Val66Met polymorphism modulates the functional impact of the IL1β-miR-142-3p axis on MS.
• This interaction offers novel insights into the heterogeneity of MS.
• Understanding this genetic influence is crucial for advancing personalized medicine strategies in multiple sclerosis.